{'fraction_non_alphanumeric': 0.06256983240223464, 'fraction_numerical': 0.06312849162011173, 'mean_word_length': 4.102564102564102, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Effect of Seventy-Two-Hour Continuous Infusion of Long-Acting Natriuretic Peptide on Acute Ischemic Renal Failure in the Rat

Objectives. Atrial natriuretic peptide (ANP1-28) protects the kidneys against acute renal failure in animals; however, its use in humans has been disappointing. Long-acting natriuretic peptide (LANP1-30) has natriuretic and diuretic actions similar to ANP1-28, but it has a longer half-life and a different receptor site. Therefore, this study's aim was to determine if LANP1-30 has better renal protection than ANP1-28, which may make it useful in the treatment of acute renal failure. Subjects/Methods. Three groups of male Sprague-Dawley rats were used, each with a body weight between 250-300 gm. Group 1 (ischemia only, n = 6) had a right nephrectomy followed by 30 minutes of left renal pedicle clamping. Group 2 (LANP Peptide treated, n = 7) had renal ischemia similar to Group 1, followed by an intraperitoneal bolus of 10 μg of LANP1-30 and the placement of mini-osmotic pumps delivering LANP1-30 at a rate of 1μg/hr for 72 hours. Group 3 (controls, n = 6) was used to measure the baseline creatinine level and had no renal ischemia or surgery. Results. Seventy-two hours post-renal ischemia, the weight loss in the ischemia group was similar to the peptide treated group (7.65 ± 1.14% and 10.03 ± 0.9% body weight loss, respectively, p = 0.126). The ischemia group had significantly higher creatinine levels compared to the controls (66.3 ± 5.3 versus 30.1 ± 0.9 μmol/L, p = 0.002). The peptide-treated group had higher creatinine (174.1 ± 77.8 versus 66.3 ± 5.3 μmol/L, p = 0.035) and LANP1-30 levels (673.14 ± 69.64 versus 45.83 ± 8.45 pg/mL, p = 0.001) than the ischemia group. Conclusion. Prolonged use of LANP1-30 has no renal protective effect.